Predicting overall vaccine efficacy in a new setting by re-calibrating baseline covariate and intermediate response endpoint effect modifiers of type-specific vaccine efficacy
DOI10.1515/EM-2015-0007zbMath1416.92111OpenAlexW2550539193WikidataQ38982807 ScholiaQ38982807MaRDI QIDQ2001894
Publication date: 11 July 2019
Published in: Epidemiologic Methods (Search for Journal in Brave)
Full work available at URL: http://europepmc.org/articles/pmc5279575
clinical trialscase-cohort designgeneralizabilityprincipal stratificationcase-control designimmune correlate of protectionvaccine efficacy trial
Applications of statistics to biology and medical sciences; meta analysis (62P10) Medical epidemiology (92C60)
Related Items (1)
Uses Software
Cites Work
- Unnamed Item
- Mark‐Specific Hazard Ratio Model with Multivariate Continuous Marks: An Application to Vaccine Efficacy
- Bayesian inference for causal effects: The role of randomization
- Assessing surrogate endpoints in vaccine trials with case-cohort sampling and the Cox model
- Design and Estimation for Evaluating Principal Surrogate Markers in Vaccine Trials
- Principal Stratification in Causal Inference
- The Probability of Causation under a Stochastic Model for Individual Risk
- The 2-sample problem for failure rates depending on a continuous mark: an application to vaccine efficacy
- Evaluating Candidate Principal Surrogate Endpoints
- The Analysis of Failure Times in the Presence of Competing Risks
- Augmented Designs to Assess Immune Response in Vaccine Trials
- Super Learner
- Measurement Error in Nonlinear Models
- Direct and Indirect Effects
- External Validity: From Do -Calculus to Transportability Across Populations
- Design of observational studies
This page was built for publication: Predicting overall vaccine efficacy in a new setting by re-calibrating baseline covariate and intermediate response endpoint effect modifiers of type-specific vaccine efficacy
